Citations (85)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Zhihao Liu, Mingjian Liu, Zhenqing Cao, Pengsen Qiu & Gaopeng Song. (2022) Phosphodiesterase‑4 inhibitors: a review of current developments (2013–2021). Expert Opinion on Therapeutic Patents 32:3, pages 261-278.
Read now
Read now
Fuminori Ohba, Shunji Matsuki, Shuhei Imayama, Kyoko Matsuguma, Seiichiro Hojo, Maiko Nomoto & Hideto Akama. (2016) Efficacy of a novel phosphodiesterase inhibitor, E6005, in patients with atopic dermatitis: An investigator-blinded, vehicle-controlled study. Journal of Dermatological Treatment 27:5, pages 467-472.
Read now
Read now
Fuminori Ohba, Maiko Nomoto, Seiichiro Hojo & Hideto Akama. (2016) Safety, tolerability and pharmacokinetics of a novel phosphodiesterase inhibitor, E6005 ointment, in healthy volunteers and in patients with atopic dermatitis. Journal of Dermatological Treatment 27:3, pages 241-246.
Read now
Read now
Ana Martinez & Carmen Gil. (2014) cAMP-specific phosphodiesterase inhibitors: promising drugs for inflammatory and neurological diseases. Expert Opinion on Therapeutic Patents 24:12, pages 1311-1321.
Read now
Read now
Jerry J Flores, Yang Zhang, Damon W Klebe, Tim Lekic, Weiling Fu & John H Zhang. (2014) Small molecule inhibitors in the treatment of cerebral ischemia. Expert Opinion on Pharmacotherapy 15:5, pages 659-680.
Read now
Read now
Mary Gregory & Daniel G Cyr. (2014) The blood-epididymis barrier and inflammation. Spermatogenesis 4:2.
Read now
Read now
Amadeu Gavaldà & Richard S Roberts. (2013) Phosphodiesterase-4 inhibitors: a review of current developments (2010 – 2012). Expert Opinion on Therapeutic Patents 23:8, pages 997-1016.
Read now
Read now
Jay H. Chung. (2012) Metabolic benefits of inhibiting cAMP-PDEs with resveratrol. Adipocyte 1:4, pages 256-258.
Read now
Read now
Mark A Giembycz & Stephen K Field. (2010) Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD. Drug Design, Development and Therapy 4, pages 147-158.
Read now
Read now
Articles from other publishers (76)
Weize Gao, Zhan Wang, Wenshuai Li, Yongxin Li & Mingjun Liu. (2023) Biomarkers and biologics related with psoriasis and psoriatic arthritis. International Immunopharmacology 122, pages 110646.
Crossref
Crossref
Emma J. Kooistra, Kilian Dahm, Antonius E. van Herwaarden, Jelle Gerretsen, Melanie Nuesch Germano, Karoline Mauer, Ruben L. Smeets, Sjef van der Velde, Maarten J. W. van den Berg, Johannes G. van der Hoeven, Anna C. Aschenbrenner, Joachim L. Schultze, Thomas Ulas, Matthijs Kox & Peter Pickkers. (2023) Molecular mechanisms and treatment responses of pulmonary fibrosis in severe COVID-19. Respiratory Research 24:1.
Crossref
Crossref
Dhritiman Roy, Shivaramakrishnan Balasubramanian, Praveen Thaggikuppe Krishnamurthy, Piyong Sola & Emdormi Rymbai. (2023) Phosphodiesterase-4 Inhibition in Parkinson’s Disease: Molecular Insights and Therapeutic Potential. Cellular and Molecular Neurobiology 43:6, pages 2713-2741.
Crossref
Crossref
Jian Jin, Francesca Mazzacuva, Letizia Crocetti, Maria Paola Giovannoni & Agostino Cilibrizzi. (2023) PDE4 Inhibitors: Profiling Hits through the Multitude of Structural Classes. International Journal of Molecular Sciences 24:14, pages 11518.
Crossref
Crossref
Carla S. Sousa, Rui Lima, Jorge R. Cibrão, Eduardo D. Gomes, Luís S. Fernandes, Tiffany S. Pinho, Deolinda Silva, Jonas Campos, António J. Salgado & Nuno A. Silva. (2023) Pre-Clinical Assessment of Roflumilast Therapy in a Thoracic Model of Spinal Cord Injury. Pharmaceutics 15:5, pages 1556.
Crossref
Crossref
Yang Zheng, Susanne Schroeder, Georgi K. Kanev, Sanaa S. Botros, Samia William, Abdel-Nasser A. Sabra, Louis Maes, Guy Caljon, Carmen Gil, Ana Martinez, Irene G. Salado, Koen Augustyns, Ewald Edink, Maarten Sijm, Erik de Heuvel, Iwan J. P. de Esch, Tiffany van der Meer, Marco Siderius, Geert Jan Sterk, David Brown & Rob Leurs. (2023) To Target or Not to Target Schistosoma mansoni Cyclic Nucleotide Phosphodiesterase 4A?. International Journal of Molecular Sciences 24:7, pages 6817.
Crossref
Crossref
Siyu Song, Lu Ding, Guangwen Liu, Tian Chen, Meiru Zhao, Xueyan Li, Min Li, Hongyu Qi, Jinjin Chen, Ziyuan Wang, Ying Wang, Jing Ma, Qi Wang, Xiangyan Li & Zeyu Wang. (2023) The protective effects of baicalin for respiratory diseases: an update and future perspectives. Frontiers in Pharmacology 14.
Crossref
Crossref
Gang Li, Dengqin He, Xiaojia Cai, Wen Guan, Yali Zhang, Jia-Qiang Wu & Hongliang Yao. (2023) Advances in the development of phosphodiesterase-4 inhibitors. European Journal of Medicinal Chemistry 250, pages 115195.
Crossref
Crossref
Anton J.M. Roks. (2022) Phosphodiesterase-1 in the cardiovascular system. Cellular Signalling 92, pages 110251.
Crossref
Crossref
Khaled M. Darwish, Ahmad Abdelwaly, Asmaa M. Atta & Mohamed A. Helal. (2022) Discovery of tetrahydro-β-carboline- and indole-based derivatives as promising phosphodiesterase-4 inhibitors: Synthesis, biological evaluation, and molecular modeling studies. Journal of Molecular Structure 1248, pages 131491.
Crossref
Crossref
Barbara Meier-Schiesser, Mark Mellett, Marigdalia K. Ramirez-Fort, Julia-Tatjana Maul, Annika Klug, Nicola Winkelbeiner, Gabriele Fenini, Peter Schafer, Emmanuel Contassot & Lars E. French. (2021) Phosphodiesterase-4 Inhibition Reduces Cutaneous Inflammation and IL-1β Expression in a Psoriasiform Mouse Model but Does Not Inhibit Inflammasome Activation. International Journal of Molecular Sciences 22:23, pages 12878.
Crossref
Crossref
Bofei Wang & Fangrui Zhong. (2021) Practical and Asymmetric Synthesis of Apremilast Using Ellman’s Sulfinamide as a Chiral Auxiliary. Molbank 2021:3, pages M1275.
Crossref
Crossref
Hanuman Narode, Manoj Gayke, Gyanchander Eppa & Jhillu Singh Yadav. (2021) A Review on Synthetic Advances toward the Synthesis of Apremilast, an Anti-inflammatory Drug. Organic Process Research & Development 25:7, pages 1512-1523.
Crossref
Crossref
Sung-Jun Park, Faiyaz Ahmad, Robert J. Bahde, Andrew Philp, Jeonghan Kim, Tianjiao Huang, Myung K. Kim, William C. Trenkle & Jay H. Chung. (2021) Potent PDE4 inhibitor activates AMPK and Sirt1 to induce mitochondrial biogenesis. PLOS ONE 16:6, pages e0253269.
Crossref
Crossref
Nagarajan Kuppuswamy, Srinivas Nanduri & Venkateswarlu Akella. 2021. Drug Discovery and Drug Development. Drug Discovery and Drug Development
303
376
.
Abid Bhat, Bipul Ray, Arehally Marappa Mahalakshmi, Sunanda Tuladhar, DN Nandakumar, Malathi Srinivasan, Musthafa Mohamed Essa, Saravana Babu Chidambaram, Gilles J. Guillemin & Meena Kishore Sakharkar. (2020) Phosphodiesterase-4 enzyme as a therapeutic target in neurological disorders. Pharmacological Research 160, pages 105078.
Crossref
Crossref
Heng Li, Jianping Zuo & Wei Tang. (2018) Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases. Frontiers in Pharmacology 9.
Crossref
Crossref
Richard S. Roberts, Sara Sevilla, Manel Ferrer, Joan Taltavull, Begoña Hernández, Victor Segarra, Jordi Gràcia, Martin D. Lehner, Amadeu Gavaldà, Miriam Andrés, Judit Cabedo, Dolors Vilella, Peter Eichhorn, Elena Calama, Carla Carcasona & Montserrat Miralpeix. (2018)
4-Amino-7,8-dihydro-1,6-naphthyridin-5(6
H
)-ones as Inhaled Phosphodiesterase Type 4 (PDE4) Inhibitors: Structural Biology and Structure–Activity Relationships
. Journal of Medicinal Chemistry 61:6, pages 2472-2489.
Crossref
Crossref
Larry Yet. 2018. Privileged Structures in Drug Discovery. Privileged Structures in Drug Discovery
15
58
.
Renan Fernandes Espírito-Santo, Cassio Santana Meira, Rafael dos Santos Costa, Otávio Passos Souza Filho, Afranio Ferreira Evangelista, Gustavo Henrique Goulart Trossini, Glaucio Monteiro Ferreira, Eudes da Silva Velozo, Cristiane Flora Villarreal & Milena Botelho Pereira Soares. (2017) The anti-inflammatory and immunomodulatory potential of braylin: Pharmacological properties and mechanisms by in silico, in vitro and in vivo approaches. PLOS ONE 12:6, pages e0179174.
Crossref
Crossref
Edmond Differding. (2017) The Drug Discovery and Development Industry in India-Two Decades of Proprietary Small-Molecule R&D. ChemMedChem 12:11, pages 786-818.
Crossref
Crossref
Sara Guariento, Anna Karawajczyk, James A. Bull, Gessica Marchini, Martyna Bielska, Xenia Iwanowa, Olga Bruno, Paola Fossa & Fabrizio Giordanetto. (2017) Design and synthesis of 4,5,6,7‐tetrahydro‐1 H ‐1,2‐diazepin‐7‐one derivatives as a new series of Phosphodiesterase 4 (PDE4) inhibitors. Bioorganic & Medicinal Chemistry Letters 27:1, pages 24-29.
Crossref
Crossref
Anjana Munshi & Satrupa Das. 2017. Phosphodiesterases: CNS Functions and Diseases. Phosphodiesterases: CNS Functions and Diseases
445
461
.
Wilhelm Schänzer & Mario Thevis. (2017) Human sports drug testing by mass spectrometry. Mass Spectrometry Reviews 36:1, pages 16-46.
Crossref
Crossref
Jordi Gràcia, Maria Antonia Buil, Jordi Castro, Peter Eichhorn, Manel Ferrer, Amadeu Gavaldà, Begoña Hernández, Victor Segarra, Martin D. Lehner, Imma Moreno, Lluís Pagès, Richard S. Roberts, Jordi Serrat, Sara Sevilla, Joan Taltavull, Miriam Andrés, Judit Cabedo, Dolors Vilella, Elena Calama, Carla Carcasona & Montserrat Miralpeix. (2016) Biphenyl Pyridazinone Derivatives as Inhaled PDE4 Inhibitors: Structural Biology and Structure–Activity Relationships. Journal of Medicinal Chemistry 59:23, pages 10479-10497.
Crossref
Crossref
Gopalan Balasubramanian, Sukunath Narayanan, Lavanya Andiappan, Thirunavukkarasu Sappanimuthu, Saravanan Thirunavukkarasu, Shamundeeswari Sundaram, Saravanakumar Natarajan, Naresh Sivaraman, Sridharan Rajagopal, Fakrudeen Ali Ahamed Nazumudeen, Sanjeev Saxena, Santosh L. Vishwakarma, Shridhar Narayanan, Ganapavarapu V.R. Sharma, Chidambaram V. Srinivasan & Narasimhan Kilambi. (2016) In vivo effective dibenzo[b,d]furan-1-yl-thiazoles as novel PDE-4 inhibitors. Bioorganic & Medicinal Chemistry 24:22, pages 5702-5716.
Crossref
Crossref
Tanaji T. Talele. (2016) The “Cyclopropyl Fragment” is a Versatile Player that Frequently Appears in Preclinical/Clinical Drug Molecules. Journal of Medicinal Chemistry 59:19, pages 8712-8756.
Crossref
Crossref
Anu P. Abhimannue, Mohind C. Mohan & Prakash Kumar B. (2016) Inhibition of Tumor Necrosis Factor-α and Interleukin-1β Production in Lipopolysaccharide-Stimulated Monocytes by Methanolic Extract of Elephantopus scaber Linn and Identification of Bioactive Components. Applied Biochemistry and Biotechnology 179:3, pages 427-443.
Crossref
Crossref
Monica Mazzarino, Lorenzo Cesarei, Xavier de la Torre, Ilaria Fiacco, Paul Robach & Francesco Botrè. (2016) A multi-targeted liquid chromatography–mass spectrometry screening procedure for the detection in human urine of drugs non-prohibited in sport commonly used by the athletes. Journal of Pharmaceutical and Biomedical Analysis 117, pages 47-60.
Crossref
Crossref
Jacques Le Roux, Caroline Leriche, Philippe Chamiot-Clerc, John Feutrill, Frank Halley, David Papin, Nathalie Derimay, Christelle Mugler, Claudine Grépin & Laurent Schio. (2016) Preparation and optimization of pyrazolo[1,5- a ]pyrimidines as new potent PDE4 inhibitors. Bioorganic & Medicinal Chemistry Letters 26:2, pages 454-459.
Crossref
Crossref
Amitava Mitra, Aquiles Leyes, Kimberly Manser, Brad Roadcap, Christine Mestre, Daniel Tatosian, Lan Jin & Naoto Uemura. (2015) Use of Minipig Skin Biopsy Model as an Innovative Tool to Design Topical Formulation to Achieve Desired Pharmacokinetics in Humans. Journal of Pharmaceutical Sciences 104:5, pages 1701-1708.
Crossref
Crossref
Nadia Moretto, Paola Caruso, Raffaella Bosco, Gessica Marchini, Fiorella Pastore, Elisabetta Armani, Gabriele Amari, Andrea Rizzi, Eleonora Ghidini, Renato De Fanti, Carmelida Capaldi, Laura Carzaniga, Emilio Hirsch, Carola Buccellati, Angelo Sala, Chiara Carnini, Riccardo Patacchini, Maurizio Delcanale, Maurizio Civelli, Gino Villetti & Fabrizio Facchinetti. (2015) CHF6001 I: A Novel Highly Potent and Selective Phosphodiesterase 4 Inhibitor with Robust Anti-Inflammatory Activity and Suitable for Topical Pulmonary Administration. Journal of Pharmacology and Experimental Therapeutics 352:3, pages 559-567.
Crossref
Crossref
Kentaro Kawai, Yusuke Endo, Takeshi Asano, Seiji Amano, Keisuke Sawada, Noriko Ueo, Nobuaki Takahashi, Yo Sonoda, Mika Nagai, Noriyuki Kamei & Naoya Nagata. (2014)
Discovery of 2-(Cyclopentylamino)thieno[3,2-
d
]pyrimidin-4(3
H
)-one Derivatives as a New Series of Potent Phosphodiesterase 7 Inhibitors
. Journal of Medicinal Chemistry 57:23, pages 9844-9854.
Crossref
Crossref
Mario Thevis & Wilhelm Schänzer. (2014) Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls. Journal of Pharmaceutical and Biomedical Analysis 101, pages 66-83.
Crossref
Crossref
Sandro Boland, Jo Alen, Arnaud Bourin, Karolien Castermans, Nicki Boumans, Laura Panitti, Jessica Vanormelingen, Dirk Leysen & Olivier Defert. (2014) Novel Roflumilast analogs as soft PDE4 inhibitors. Bioorganic & Medicinal Chemistry Letters 24:18, pages 4594-4597.
Crossref
Crossref
Zhong-Bin Cheng, Ya-Lin Deng, Cheng-Qi Fan, Qing-Hua Han, Shu-Ling Lin, Gui-Hua Tang, Hai-Bin Luo & Sheng Yin. (2014)
Prostaglandin Derivatives: Nonaromatic Phosphodiesterase-4 Inhibitors from the Soft Coral
Sarcophyton ehrenbergi
. Journal of Natural Products 77:8, pages 1928-1936.
Crossref
Crossref
Rashika Joshi, Nijiati Kadeer, Sulaiman Sheriff, Lou Ann Friend, J. Howard James & Ambikaipakan Balasubramaniam. (2014) Phosphodiesterase (PDE) inhibitor torbafylline (HWA 448) attenuates burn-induced rat skeletal muscle proteolysis through the PDE4/cAMP/EPAC/PI3K/Akt pathway. Molecular and Cellular Endocrinology 393:1-2, pages 152-163.
Crossref
Crossref
Oliver FitzGerald. (2014) Apremilast: welcome advance in treatment of psoriatic arthritis. Nature Reviews Rheumatology 10:7, pages 385-386.
Crossref
Crossref
Elisabetta Armani, Gabriele Amari, Andrea Rizzi, Renato De Fanti, Eleonora Ghidini, Carmelida Capaldi, Laura Carzaniga, Paola Caruso, Matilde Guala, Ilaria Peretto, Elena La Porta, Pier T. Bolzoni, Fabrizio Facchinetti, Chiara Carnini, Nadia Moretto, Riccardo Patacchini, Franco Bassani, Valentina Cenacchi, Roberta Volta, Francesco Amadei, Silvia Capacchi, Maurizio Delcanale, Paola Puccini, Silvia Catinella, Maurizio Civelli & Gino Villetti. (2014) Novel Class of Benzoic Acid Ester Derivatives as Potent PDE4 Inhibitors for Inhaled Administration in the Treatment of Respiratory Diseases. Journal of Medicinal Chemistry 57:3, pages 793-816.
Crossref
Crossref
Daniela Bianchi, Pasquale De Michele, Cristina Marchetti, Brunello Tirozzi, Salvatore Cuomo, Hélène Marie & Michele Migliore. (2014) Effects of increasing CREB-dependent transcription on the storage and recall processes in a hippocampal CA1 microcircuit. Hippocampus 24:2, pages 165-177.
Crossref
Crossref
Ling Huang, Wenjun Shan, Qi Zhou, Jiaxing Xie, Kefang Lai & Xingshu Li. (2014) Design, synthesis and evaluation of dual pharmacology β2-adrenoceptor agonists and PDE4 inhibitors. Bioorganic & Medicinal Chemistry Letters 24:1, pages 249-253.
Crossref
Crossref
Taiji Goto, Akiko Shiina, Toshiharu Yoshino, Kiyoshi Mizukami, Kazuki Hirahara, Osamu Suzuki, Yoshitaka Sogawa, Tomoko Takahashi, Tsuyoshi Mikkaichi, Naoki Nakao, Mizuki Takahashi, Masashi Hasegawa & Shigeki Sasaki. (2013) Synthesis and biological evaluation of 5-carbamoyl-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors. Bioorganic & Medicinal Chemistry 21:22, pages 7025-7037.
Crossref
Crossref
Frank Wunder, Ramona Quednau, Andreas Geerts, Martina Barg & Adrian Tersteegen. (2013) Characterization of the Cellular Activity of PDE 4 Inhibitors Using Two Novel PDE 4 Reporter Cell Lines. Molecular Pharmaceutics 10:10, pages 3697-3705.
Crossref
Crossref
Manel Ferrer, Richard S. Roberts & Sara Sevilla. (2013) A modular synthesis of novel 4-amino-7,8-dihydro-1,6-naphthyridin-5(6H)-ones as PDE4 inhibitors. Tetrahedron Letters 54:36, pages 4821-4825.
Crossref
Crossref
Peter Kraft, Tobias Schwarz, Eva Göb, Nadine Heydenreich, Marc Brede, Sven G. Meuth & Christoph Kleinschnitz. (2013) The phosphodiesterase-4 inhibitor rolipram protects from ischemic stroke in mice by reducing blood–brain-barrier damage, inflammation and thrombosis. Experimental Neurology 247, pages 80-90.
Crossref
Crossref
Rainer Gewald, Christian Grunwald & Ute Egerland. (2013) Discovery of triazines as potent, selective and orally active PDE4 inhibitors. Bioorganic & Medicinal Chemistry Letters 23:15, pages 4308-4314.
Crossref
Crossref
Naoto Ishii, Manabu Shirato, Hisashi Wakita, Kazuki Miyazaki, Yasutaka Takase, Osamu Asano, Kazutomi Kusano, Eiichi Yamamoto, Chiharu Inoue & Ieharu Hishinuma. (2013) Antipruritic Effect of the Topical Phosphodiesterase 4 Inhibitor E6005 Ameliorates Skin Lesions in a Mouse Atopic Dermatitis Model. Journal of Pharmacology and Experimental Therapeutics 346:1, pages 105-112.
Crossref
Crossref
Anke Heuser, Lars Mecklenburg, Deborah Ockert, Manfred Kohler & Jörg Kemkowski. (2012) Selective Inhibition of PDE4 in Wistar Rats Can Lead to Dilatation in Testis, Efferent Ducts, and Epididymis and Subsequent Formation of Sperm Granulomas. Toxicologic Pathology 41:4, pages 615-627.
Crossref
Crossref
Taiji Goto, Akiko Shiina, Toshiharu Yoshino, Kiyoshi Mizukami, Kazuki Hirahara, Osamu Suzuki, Yoshitaka Sogawa, Tomoko Takahashi, Tsuyoshi Mikkaichi, Naoki Nakao, Mizuki Takahashi, Masashi Hasegawa & Shigeki Sasaki. (2013) Identification of the fused bicyclic 4-amino-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors. Bioorganic & Medicinal Chemistry Letters 23:11, pages 3325-3328.
Crossref
Crossref
Mario Thevis, Oliver Krug & Wilhelm Schänzer. (2013) Monitoring phosphodiesterase-4 inhibitors using liquid chromatography/(tandem) mass spectrometry in sports drug testing. Rapid Communications in Mass Spectrometry 27:9, pages 993-1004.
Crossref
Crossref
Pierre Voisin & Marianne Bernard. (2013) Cyclic AMP-dependent regulation of tyrosine hydroxylase mRNA and immunofluorescence levels in rat retinal precursor cells. Cell and Tissue Research 352:2, pages 207-216.
Crossref
Crossref
Joseph D. Panarese & Craig W. Lindsley. (2012) Biomimetic Synthesis and Biological Evaluation of Aplidiopsamine A. Organic Letters 14:22, pages 5808-5810.
Crossref
Crossref
Georg Schett, Jurgen Wollenhaupt, Kim Papp, Rik Joos, Jude F. Rodrigues, Adele R. Vessey, ChiaChi Hu, Randall Stevens & Kurt L. de Vlam. (2012) Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter, randomized, double‐blind, placebo‐controlled study. Arthritis & Rheumatism 64:10, pages 3156-3167.
Crossref
Crossref
Arthur E. Kümmerle, Martine Schmitt, Suzana V. S. Cardozo, Claire Lugnier, Pascal Villa, Alexandra B. Lopes, Nelilma C. Romeiro, Hélène Justiniano, Marco A. Martins, Carlos A. M. Fraga, Jean-Jacques Bourguignon & Eliezer J. Barreiro. (2012)
Design, Synthesis, and Pharmacological Evaluation of
N
-Acylhydrazones and Novel Conformationally Constrained Compounds as Selective and Potent Orally Active Phosphodiesterase-4 Inhibitors
. Journal of Medicinal Chemistry 55:17, pages 7525-7545.
Crossref
Crossref
Debra J Reid & Nga T Pham. (2012) Roflumilast: A Novel Treatment for Chronic Obstructive Pulmonary Disease. Annals of Pharmacotherapy 46:4, pages 521-529.
Crossref
Crossref
Thérèse Keravis & Claire Lugnier. (2012) Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments. British Journal of Pharmacology 165:5, pages 1288-1305.
Crossref
Crossref
Jan Lötvall & Bo Lundbäck. 2012. Advances in Combination Therapy for Asthma and COPD. Advances in Combination Therapy for Asthma and COPD
296
310
.
Chung-Hung Shih, Ling-Hung Lin, Hsin-Te Hsu, Kuo-Hsien Wang, Chi-Yin Lai, Chien-Ming Chen & Wun-Chang Ko. (2012) Hesperetin, a Selective Phosphodiesterase 4 Inhibitor, Effectively Suppresses Ovalbumin-Induced Airway Hyperresponsiveness without Influencing Xylazine/Ketamine-Induced Anesthesia. Evidence-Based Complementary and Alternative Medicine 2012, pages 1-10.
Crossref
Crossref
Nicholas D. Bland, Cuihua Wang, Craig Tallman, Alden E. Gustafson, Zhouxi Wang, Trent D. Ashton, Stefan O. Ochiana, Gregory McAllister, Kristina Cotter, Anna P. Fang, Lara Gechijian, Norman Garceau, Rajiv Gangurde, Ron Ortenberg, Mary Jo Ondrechen, Robert K. Campbell & Michael P. Pollastri. (2011) Pharmacological Validation of Trypanosoma brucei Phosphodiesterases B1 and B2 as Druggable Targets for African Sleeping Sickness. Journal of Medicinal Chemistry 54:23, pages 8188-8194.
Crossref
Crossref
You-Lan Yang, Hsin-Te Hsu, Kuo-Hsien Wang, Cheng-Ying Han, Chien-Ming Chen, Chi-Ming Chen & Wun-Chang Ko. (2011) Hesperetin-7,3'-O-dimethylether selectively inhibits phosphodiesterase 4 and effectively suppresses ovalbumin-induced airway hyperresponsiveness with a high therapeutic ratio. Journal of Biomedical Science 18:1.
Crossref
Crossref
SANG-DO LEE, DAVID S. C. HUI, AZIAH A. MAHAYIDDIN, CAMILO C. ROA JR, KHENG HOE KWA, UDO-MICHAEL GOEHRING, DIRK BREDENBRÖKER & HAN-PIN KUO. (2011) Roflumilast in Asian patients with COPD: A randomized placebo-controlled trial. Respirology 16:8, pages 1249-1257.
Crossref
Crossref
S.H. Christiansen, J. Selige, T. Dunkern, A. Rassov & M. Leist. (2011) Combined anti-inflammatory effects of β2-adrenergic agonists and PDE4 inhibitors on astrocytes by upregulation of intracellular cAMP. Neurochemistry International 59:6, pages 837-846.
Crossref
Crossref
Frédéric J.J. Bihel, Hélène Justiniano, Martine Schmitt, Malik Hellal, Mohamed A. Ibrahim, Claire Lugnier & Jean-Jacques Bourguignon. (2011) New PDE4 inhibitors based on pharmacophoric similarity between papaverine and tofisopam. Bioorganic & Medicinal Chemistry Letters 21:21, pages 6567-6572.
Crossref
Crossref
Joan Taltavull, Jordi Serrat, Jordi Gràcia, Amadeu Gavaldà, Mònica Córdoba, Elena Calama, José Luis Montero, Míriam Andrés, Montserrat Miralpeix, Dolors Vilella, Begoña Hernández, Jorge Beleta, Hamish Ryder & Lluís Pagès. (2011) Synthesis and biological activity of pyrido[3′,2′:4,5]furo[3,2-d]pyrimidine derivatives as novel and potent phosphodiesterase type 4 inhibitors. European Journal of Medicinal Chemistry 46:10, pages 4946-4956.
Crossref
Crossref
Klaus F. Rabe. (2011) Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. British Journal of Pharmacology 163:1, pages 53-67.
Crossref
Crossref
Wun-Chang Ko, Ling-Hung Lin, Hsin-Yi Shen, Chi-Yin Lai, Chien-Ming Chen & Chung-Hung Shih. (2011) Biochanin A, a Phytoestrogenic Isoflavone with Selective Inhibition of Phosphodiesterase 4, Suppresses Ovalbumin-Induced Airway Hyperresponsiveness. Evidence-Based Complementary and Alternative Medicine 2011, pages 1-13.
Crossref
Crossref
Hermann Tenor, Armin Hatzelmann, Rolf Beume, Gezim Lahu, Karl Zech & Thomas D. Bethke. 2011. Phosphodiesterases as Drug Targets. Phosphodiesterases as Drug Targets
85
119
.
Mark A. Giembycz & Robert Newton. 2011. Phosphodiesterases as Drug Targets. Phosphodiesterases as Drug Targets
415
446
.
Michel Gallant, Renee Aspiotis, Stephen Day, Rebecca Dias, Daniel Dubé, Laurence Dubé, Richard W. Friesen, Mario Girard, Daniel Guay, Pierre Hamel, Zheng Huang, Patrick Lacombe, Sebastien Laliberté, Jean-François Lévesque, Susana Liu, Dwight Macdonald, Joseph Mancini, Donald W. Nicholson, Angela Styhler, Karen Townson, Kerry Waters, Robert N. Young & Yves Girard. (2010) Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment. Bioorganic & Medicinal Chemistry Letters 20:22, pages 6387-6393.
Crossref
Crossref
Joan Taltavull, Jordi Serrat, Jordi Gràcia, Amadeu Gavaldà, Míriam Andrés, Mònica Córdoba, Montserrat Miralpeix, Dolors Vilella, Jorge Beleta, Hamish Ryder & Lluís Pagès. (2010)
Synthesis and Biological Activity of Pyrido[3′,2′:4,5]thieno[3,2-
d
]pyrimidines as Phosphodiesterase Type 4 Inhibitors
. Journal of Medicinal Chemistry 53:19, pages 6912-6922.
Crossref
Crossref
Chung-Hong Shih, Ling-Hung Lin, Ya-Hsin Lai, Chi-Yin Lai, Cheng-Ying Han, Chien-Ming Chen & Wun-Chang Ko. (2010) Genistein, a competitive PDE1–4 inhibitor, may bind on high-affinity rolipram binding sites of brain cell membranes and then induce gastrointestinal adverse effects. European Journal of Pharmacology 643:1, pages 113-120.
Crossref
Crossref
Fei-Peng Lee, Chwen-Ming Shih, Hsin-Yi Shen, Chien-Ming Chen, Chi-Ming Chen & Wun-Chang Ko. (2010) Ayanin, a non-selective phosphodiesterase 1–4 inhibitor, effectively suppresses ovalbumin-induced airway hyperresponsiveness without affecting xylazine/ketamine-induced anesthesia. European Journal of Pharmacology 635:1-3, pages 198-203.
Crossref
Crossref
Zhi Chen, Guanghui Tian, Zhen Wang, Hualiang Jiang, Jingshan Shen & Weiliang Zhu. (2010) Multiple Pharmacophore Models Combined with Molecular Docking: A Reliable Way for Efficiently Identifying Novel PDE4 Inhibitors with High Structural Diversity. Journal of Chemical Information and Modeling 50:4, pages 615-625.
Crossref
Crossref
Mousumi Ghosh & Damien Pearse. (2010) Cyclic AMP-specific PDEs: A promising therapeutic target for CNS repair. Translational Neuroscience 1:2.
Crossref
Crossref
Philipp Skroblin, Solveig Grossmann, Gesa Schäfer, Walter Rosenthal & Enno Klussmann. 2010.
235
330
.
Julio Cortijo Gimeno. (2010) Inhibidores de fosfodiesterasa 4: un nuevo grupo farmacológico en el tratamiento de la inflamación crónica de las vías aéreas. Archivos de Bronconeumología 46, pages 3-7.
Crossref
Crossref